Safety and efficacy outcomes from a five-year study indicate that intravitreal triamcinolone can be an appropriate treatment in selected patients with advanced diabetic macular edema. Beneficial effects persisted throughout the study period, and no unexpected adverse events were seen.
In an evaluation of the anatomic changes of CNV lesions, patients treated with ranibizumab (Lucentis, Genentech) in the PIER study had smaller changes than patients who had received sham injections.
An analysis of data from a study of eye disease in Latinos provides additional evidence that interleukin-8 (IL-8) may play a role in the development or progression of age-related macular degeneration.
Results from the Age-Related Eye Disease Study (AREDS) showed that participants assigned to take zinc dietary supplements had lower mortality than participants not assigned to zinc supplements. The long-term study also indicated that poorer survival was associated with AMD.
A telemedicine program, in which images allow patients to virtually visit with doctors, can be a valuable tool in the early detection, management, and treatment of diabetic retinopathy.
In some circumstances, it may be unnecessary to obtain images simultaneously with a confocal laser scanning system and optic disc photography, suggests a new study.
Use of spectral-domain optical coherence tomography with automated image processing seems to provide more objective and potentially more reproducible assessments of the optic nerve head when compared with ophthalmologists' assessments of conventional fundus photos.
The American Academy of Ophthalmology (AAO) is pleased to announce Harvey V. Fineberg, MD, PhD, president of the Institute of Medicine, as this year's keynote speaker.
ISTA Pharmaceuticals, Inc. has entered into an agreement with Deerfield Management, Sprout, and Sanderling Ventures, three of its long-term shareholders, to provide it with up to $65 million in financing through a flexible credit facility.
Topical, periocular, and/or systemic corticosteroids typically are used to treat corneal endothelial graft rejection. When those modalities fail, experience in a series of five eyes suggests intracameral triamcinolone acetonide may be worth considering.
Using standardized terminology, such as that in the Birmingham Eye Trauma Terminology system, to describe trauma to the globe eliminates misrepresentation of the injury.
The high-tech devices available today are changing the way ophthalmology is practiced. According to the surgeon, the new technology found in state-of-the-art optical coherence tomography goes much further than assisting ophthalmologists in the diagnostics of anterior eye and retinal disorders.
A new ketotifen fumarate ophthalmic solution (Refresh Eye Itch Relief, Allergan) offers patients another option for the treatment of episodic ocular itching as well as seasonal and chronic allergic conjunctivitis.
Times have changed, and, with them, practices in antibacterial therapy. Questions remain, however. Has progress been made over the decades, and what does the future hold?
Physicians seem to have grasped the power of the Internet to help them secure continuing medical education credits in a way that precisely meets their professional interests and time constraints.
Non-surgical blepharoplasty can provide surgeons with a minimally invasive approach to eyelid procedures.
Another piece of the puzzle of the mechanism involved in the elevation of IOP has been identified with the discovery of the role of the gene sFRP-1 in the Wnt signaling pathway.
Monotherapy is usually the first step in glaucoma therapy, but when IOP is not sufficiently lowered with a single agent, a fixed combination can be considered. The advantages, limitations, and features of fixed combinations of IOP-lowering agents available worldwide are reviewed.
Othera Pharmaceuticals Inc. has begun dosing in a phase I/II multicenter, investigator-masked clinical trial of the safety and efficacy of a topical drug (OT-730) in reducing IOP in subjects with ocular hypertension or open-angle glaucoma.
Acucela Inc. and Otsuka Pharmaceutical Co. Ltd. have entered into agreements to co-develop Otsuka's proprietary compound for the treatment of dry eye (Rebamipide), which is in phase III clinical trials in the United States, as well as Acucela's lead compound (ACU-4429), which is in phase I clinical trials for non-exudative (dry) age-related macular degeneration in the United States.
The inaugural meeting of the International Society of Bilateral Cataract Surgeons (ISBCS) was held Sept. 1, during the recent annual meeting of the European Society of Cataract and Refractive Surgeons (ESCRS).
Ophthalmic resident and fellowship education programs in the United States are responding to the changing requirements of working in a modern health-care delivery system and new incentives have been created for transforming the "apprenticeship model" to a "competency-based" model of education.
A combination of blue light exposure and low blood levels of anti-oxidants may be associated with an increased risk of neovascular age-related macular degeneration (AMD), as well as early AMD, according to research published in the October issue of Archives of Ophthalmology.
Human immunodeficiency virus (HIV) has become a manageable chronic disease, but that is true only in rich countries that have a relatively small number of HIV cases. With the evolution of treatment, patients can expect a natural life expectancy with the available therapies. These treatments are needed globally in third-world countries where most of the cases are.
Prevent Blindness America (PBA) announced the addition of three new members to its national board of directors.
Medicare is one of several health-policy decisions that many physicians, including ophthalmologists, hope to see addressed by the next president-elect.
As part of its crackdown on the use of unapproved drugs, the FDA is warning all but two makers of balanced salt solution (BSS) used in ophthalmic surgery to discontinue its manufacture and sale.
A U.S. patent has been granted to a pharmaceuticals company that will cover a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation pathways believed to be involved in age-related macular degeneration (AMD) and other ophthalmic diseases.
In this podcast, Ophthalmology Times Chief Medical Editor Peter J. McDonnell, MD, provides an overview of the AAO meeting, including the hottest topics that will be discussed. Also, Ophthalmology Times Associate Editor Christina Phillis provides tips on traveling to and getting the most of your time in Atlanta. Daily podcast coverage will feature session highlights and interviews with highly regarded specialists in ophthalmologic medicine.
A biotechnology company will be presenting its ASaP phase I clinical data for its leading drug candidate (POT-4, Potentia Pharmaceuticals) during Retina Subspecialty Day at the annual meeting of the American Academy of Ophthalmology in Atlanta Nov. 7.
